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Abstract 
As the Vancomycin is itself a nephrotoxic antibiotics, so it is sometime 
recommended to the Slow-low Efficiency Dialysis (SLED) patients against 
highly resisted infection. In this case, the dose monitoring is strictly 
maintained after Intravenous injection. The collected blood was analyzed for 
its concentration in HPLC for 11 patients and the half life was evaluated to 
study Therapeutic drug monitoring. The T1/2 of evaluated vancomycin is 
39.12+ 6.81 hrs. The mean of the systemic clearance is 16.91+6.99 and mean 
Vd   is 0.57+ 0.147. Comparatively the reported study of Mean + SD of half-
life, volume of distribution, and systemic clearance were 43.1 + 21.6 hours, 
0.84 L/kg + 0.17 L/kg, and 24.3 mL/min + 8.39 mL/min respectively. Thus 
the t-test of  the means was 0.5828, degree of freedom (df)  was 20, standard 
error of difference was 6.829 and so, the two-tailed P value is 0.5665 i.e. P > 
0.5. In ethnic Indian SLED patients, T1/2 of mean + SD of 39.12 + 6.81 hrs 
was compared to the Caucasian patients i.e, 43.1 + 21.6 hrs. And the t-test 
and P-value is 0.5828 & 0.5665 respectively. Thus it was concluded that the 
half-life of ethnic Indian patients is less in compare to Caucasians but this 
difference is not so significant. The half-life of ethnic 8 patients is less than 
40 out of 11 patients. 
 
Keywords: Vancomycin assay; Slow-low efficiency dialysis; 
Pharmacokinetic analysis; Ethnic indians 
Introduction  
Vancomycin  is a glycopeptide antibiotic used in the 
prophylaxis and treatment of infection caused by Gram  
+ve bacteria [1]. Its “last resort” antibiotic after the 
failure with other antibiotics. Vancomycin prevents 
incorporation of N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG)- peptide subunits into the 
peptidoglycan matrix; which forms the major structural 
component of gram +ve cell walls[2]. Its clinically 
used in the treatment of methicilline resistant 
staphylococcus aureus (MRSA), multiresistant staphy- 
lococcus  epidermidis  (MRSE),   pseudomembraneous 
 
 
colitis (relapse), prophylaxis for endocarditis and 
individual serious allergy to penicillins or β- lactum 
antimicrobials [3]. Vancomycin is intrinsically 
resistance to gram +ve Leuconostoc and pediococcus 
species and gram –ve non-gonococcal Neisseria 
species, also acquired microbial resistance Enterococci 
(Enterococcus faecium & E. faccalis). Vancomycin has 
common adverse drug reaction with IV include: local 
pain, which may be severe and /thrombophlebitis, 
Nephrotoxicity and ototoxicity, also rare adverse 
effects  of  anaphylaxis,  erythema  multiforme, redman  
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syndrome, superinfection, thrombocytopenia, 
neutropenia, leucopenia, tinnitus, dizziness and toxic 
epidermal necrolysis. 
In hospital it was seen that due to above mention gram 
-ve bacterial infection of resistant species responsible 
effectively in nephro patients like ARF and CRF, were 
kept in haemodialysis like Intermediate Haemodialysis 
(IHD) and Slow- low efficiency Dialysis (SLED) 
having the last choice of aminoglycoside, vancomycin. 
SLED is a modified from of intermittend hamodialysis 
(IHD) with altered blood and low dialysate flow 
rates[4,5]. SLED has been performed daily over a 6 to 
12 hrs period. On focusing its nephrotoxic nature of 
their antibiotics and its choice of IV administration at 
last stage of treatment, the requirement exist to control 
the dose of administration. Regarding this the 
therapeutic drug dose monitoring is very much 
essential aspects. So, need arises to identify the SLED 
patient administered with vancomycin (IV) Clinicians 
in hospital wards to admitted patients[6, 7]. Such 11 
SLED patients were identified in AMRI hospital, 
Dakuria, Kolkata for 9 month study period. Blood were 
collected to evaluate the Therapuetic Drug Monitoring 
purpose with the help sophisticated HPLC instruments. 
To evaluate pharmacokinetic and Pharmacodynamics 
parameters, the concentration of the vancomycin was 
estimated through the peak arises in chromatogram 
with the help of reverse phase HPLC, isocratic 
methods. The available pharmacokinetic and 
pharmacodynamic datas of ethnic patients were 
estimated and which was comparatively studied with 
the datas of Caucasian patients. 
 
Materials and methods 
Design  
We arrange a prospective pharmacokinetic study of 
vancomycin between Sep, 2008 to May, 2009 on 1st 
class academic level-based superspeciality hospital 
having 500 beds. Adult patients above 18 years, with 
actual body weight within 30% of ideal body weight, 
ethnic Indian, SLED patients received concurrent 
vancomycin suffering from renal failure. 
Patients receiving vancomycin preceeding 5 weeks, 
with severe liver disease, hospitalized less than 5days; 
obese, cystic, fibrosis, Malignant and burn patients 
were excluded from investigation. 
For the study of RF patients, the proposal made 
approved from AMRI Hospital Ethical committee. 
 
Study Protocol  
Vancomycin was injected intravenously by the 
clinicians with doses recommended usually in practice. 
Patients who started vancomycin after initiation of 
SLED therapy had serum vancomycin concentration 
drawn after 1hr of infusion and again drawn befor half 
an hour of 2nd infusion of vancomycin IV during SLED. 
The redosing were usually given by clinicians when the 
serum concentration was less than 20 mcg/ml. The 
vancomycin concentration was not used for the 
pharmacokinetic analysis, it was measured to ensure 
that the vancomycin serum concentration had not fallen 
too low. 
 
Table 1.  Area & Height peaks of standard 
vancomycin solution. 
 
Conc. 
Micro.gm
Figures Retention 
Time 
Height 
of 
Peaks 
[mV] 
Area of 
Peaks 
[mV.s] 
 
5µgm 
 
FIG-A1 
 
2.57 min 
 
0.012 
 
0.12243
10µgm FIG-A2 2.57 min 0.021 0.24587
20µgm FIG-A3 2.57 min 0.031 0.48974
40µgm FIG-A4 2.57 min 0.049 0.85443
60µgm FIG-A5 2.57 min 0.051 1.28165
80µgm FIG-A6 2.57 min 0.10 1.7088 
100µgm FIG-A7 2.57 min 0.148 2.136 
 
Blood was collected when after 1hr of infusion usually 
in order to know the peak concentration of vancomycin 
and blood collected before ½ hr of second infusion is to 
know the trough concentration of vancomycin . The 
vancomycin peaks concentration were evaluated in 
HPLC, through BDS  C18 (150 X 4.6) under software 
Clarity lite (Clarity-Chromatography SW) data apex 
2003. 
 
Table 2.  Patients demography evolved. 
 
Numbers 
Gender 
Mean Age  
Mean weight 
Mean Length 
Charlson Score 
11 
9/3 
60.09 ± 11.98 
61.66 ± 11.89 
5.59 ± 0.35 
5.26 ± 1.16 
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SLED Parameter 
SLED were performed in the ICU, Nephro-dialysis unit 
and was performed as a continuous renal replacement 
therapy over 24 hrs period. SLED therapy was 
occasionally interrupted because of scheduled 
equipment cleansing or blood clotting. Blood flow rate 
(BFR) was set at 200/min with  the dialysate running at  
 
100ml/min. Dialysate solution was produced online 
using concentrated solution  and treated tap water. The 
dialysate solution was drained directly into the sink, of 
F5, F6, F7 (Fresenies Medical care) hemodialyzers 
prescribed for SLED. 
 
 
Table 3.  Pharmacokinetic data evaluated in 11 patients after calculation. 
 
 
Vancomycin Assay 
To evaluate the concentration of the vancomycin in the 
blood plasma analysis, caliberation of the vancomycin 
estimation parameters were hardly needed with the 
help of standardization of vancomycin[8]. As the 
standard vancomycin collected (Central drug lab., 
Kolkata) and after running into same HPLC  machine 
gives AUC at retention time RT-2.57min . The 
concentration of phosphate buffer is 50 mmol /L 
(sonicated )  given  in  isocratic   method  of   95:5   of  
HPLC grade water: Acetonitrile. The parameter of the 
detector is maintained at 270nm wavelength, the flow 
rate of sample is HPLC cannel is 0.8ml/min, pH 
maintained of buffer is 3.2 pH. After running the 
standard solution of the vancomycin through above 
HPLC machine with above mention parameter the 
result of peaks obtained is represented in Figure 1. 
Patient’s 
Samples 
Plasma 
Peak 
conc. 
Plasma 
Tough 
conc. 
 
 
Rate of  ele 
-mination 
(Kel ) 
Creatinine 
Clearance 
CrCl(ml/min) 
Clearance 
CLs 
(ml/min) 
Vd(L/kg) T1/2 (hr) Haemo- 
dialyser 
 
SP-1 45 16 0.017 14.45 
 
10.88 0.82 40.76 F6 
 
SP-2 46.2 14 0.019 
 
44.55 
 
33.46 0.82 36.47 F7 
SP-3 45.6 15 0.018 20.9 
 
15.72 0.51 38.5 F6 
SP-4 44 15.6 0.017 30.36 
 
22.82 0.58 40.76 F5 
SP-5 48 13.3 0.021 
 
17.4 
 
13.1 0.47 33 F5 
SP-6 37.40 17 0.013 27.90 
 
20.97 0.70 53.3 F6 
SP-7 45.87 18 0.015 
 
16.07 
 
12.07 0.46 46.2 F6 
SP-8 46 17.2 0.016 
 
15.17 
 
11.42 0.56 43.31 F6 
SP-9 45.85 14.1 0.019 21.27 
 
20.95 0.45 36.47 F6 
SP-10 45.90 12.2 0.022 16.8 
 
12.69 0.43 31.5 F5 
SP-11 46.27 11 0.023 15.91 
 
11.97 0.45 30.13 F5 
Mean +  
SD 
45.09 
±2.72 
14.64 
±2.17 
NA 
 
NA 16.91 
± 6.99 
0.57 ± 
0.147 
39.12± 
6.81 
NA 
SEM  2.0533  
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The above peak obtained in the HPLC was ploted as 
the voltage (mV.s) Vs time intervals for 
5,10,20,40,60,80,100µgm / ml concentration in Figure 
1.  According to that the Table 1 represents the Height 
of peak (mV) , Area of peaks(mV.s) , Retention time 
(RT) against respective concentration. In Table 1, FIG- 
A1,A2,A3,A4,A5,A6 & A7 represents the peaks 
plotted, which is remarked in Figure 1. 
 
 
 
Figure  1.   Standardization of vancomycin AUC 
under following parameters. 
 
According to figure 2, the area of the peaks (AUC) in 
mV.s were taken to plot a near about straight or linear 
graph with the respect of concentration (µg/ml). This 
graph represents the equation: y=a+b*x; linear 
regession: r2 = 0.99428; Slope: 0.050915;   Intercepts: 
-0.0624. That’s why on going through the linear 
regression, this slop of graph was considered. 
Standardization of  vancomycin was done after many 
variation in parameters in order to maintain the 
maximum retention time so that overlapping of the 
peaks area with the other drugs in the serum can be 
avoided. 
 
 
Figure  2.  Standardization curve of vancomycin; 
Area (AUC) of peak Vs Concentration µg/ml. 
 
After standardization of vancomycin concentration 
with AUC, the concentration for the peak level and 
trough level of 11 SLED patients were evaluated. So, 
Blood samples were collected from the patient in a red 
tube and was transferred to the laboratory for 
centrifugation at a 5000 rpm serum collected and stored 
at -20 °C .Before experiment it was mixed with di-
methyl-sulfoxide [DMSO] and internal standard I.S., 
centrifuge at 5000rpm supernatant spike serum was 
then collected in 20 mcL in injection to run through 
HPLC. Internal standards(IS) are very much essentials 
for the bioassays. Here, in this HPLC assay five  
Internal Standard (IS)  were used – Imipramine, 
Nebivolol, Ondanosatron, Aceclofenac, Ibuprofen 
having retention time 2.56, 2.54, 2.49,2.83  2.36 min 
respectively. From above IS ondanosatron was selected 
of 60 µg/ml to the injected 11 samples shown in Figure 
3 & 4 for peak and tough  level on 5 patients. 
Concentration  of  vancomycin (vanco) was estimated 
from AUC of vancomycin with respect to ondanosatron 
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(ondan). Thus so evaluate the accuracy in peaks areas 
of the spiked serum proportionally. 
 
Pharmacokinetic Analysis 
Serum Vancomycin concentration were used to 
determine the elimination rate constant (Kel), 
elimination rate constant (Kel) , elimination half-life 
(T1/2), volume of distribution (Vd), and systemic 
clearance (CLs). The study assumed a one-
compartment IV bolus model for pharmacokinetics 
calculation. 
 
 
Figure 3.  Five patient sample of spiked blood with 
60µg/ml IS from SP1 to SP 5 for peak   level AUC. 
The elimination rate constant was determined by 
performing an unweighted linear least – squares 
regression analysis with the logarithms of the patients 
serum vancomycin concentrations. The elimination T1/2 
was then calculated based on a first-order elimination 
process, where T1/2 = 0.693/Kel. 
 
 
 
 
 
Figure  4.  Five patient sample of  spiked blood with 
60µg/ml IS from SP1 to SP 5 for trough   level AUC. 
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For patients who had not previously received 
vancomycin  Vd was determined from the extrapolated 
initial concentration –Cmax (peak concentration) and 
Cmin (trough). For patients who had received 
vancomycin prior to the pharmacokinetic evaluation, 
calculation for Vd were modified to take into account 
the residual serum vancomycin  conc. Existing from 
the previous dose: Vd= Dose/(Cmax-Cmin) where  
Cmax represented the calculated peak serum 
conc.following the first dose of vancomycin after the 
initiation of the SLED and Cmin represented the trough 
level from the vancomycin dose prior to the start of  
SLED therapy. Systemic clearance was determined 
from the calculated Kel and Vd : CLs = Kel X Vd . 
 
Results 
A total 11 patients ( 3 female & 9 male) participated at 
pharmacokinetic study. Patients demographics data are 
shown in Table 2 it was observe from mean age that 
max. patients of hospital is form upper age . Indian 
patients have the Avg. weight less then the Caucasian 
patients. From the chart of Table 3 of clinical data it 
was observed that the bilirubin, SGOT and SGPT are 
normal which indicate the patients in pharmacokinetic 
study has normal liver function or not so critical to give  
any variation much in study.  
During the collection of the data we can able to manage 
11 patient carring peaks as well as trough level of AUC 
is developed due to the limitation of correlation to 
contact/get patients collecting time schedules. It was 
well know that the creatinine clearance is co-related 
with the vancomycin clearance proportionally. In the 
formula CL= Crcl x 0.065 shows that systemic 
clearance of vancomycin –CL is 16.91+ 6.99 with the 
respect to creatinine clearance. So, as the Crcl increase 
shows simultaneously increase in systemic clearance. 
And if the systemic clearance increase then the (T1/2 ) 
of the drug , vancomycin , will reduce gradually . This 
measure the creatinine (Crcl) is inversely proportional 
to the half life (T1/2). 
 
Discussion 
In the patients with normal renal function, the T1/2 of 
vancomycin is ranges from 5.7 to 9.1 hrs . In patients 
with ARF receiving continuous renal replacement 
therapies, the vancomycin T1/2 has ranged from 4.1 to 
56.3 hrs . 
We evaluate a mean vancomycin T1/2 of 39.12+ 6.81 
hrs , which is longer than the T1/2 observed in patients 
with normal renal function but falls within the range of 
half-life that have been reported for patient receiveing 
Continuous renal replacement therapies. 
 
 
Figure 5.  Correlation of Systemic Clearance(CLs); 
Half-life (T1/2)   and  Volume of distribution  (Vd). 
 
We have observed a less degree of variability in the 
vancomycin half-life of our SLED patients. 
Vancomycin half life ranges from 30.13 to 53.3 hrs. 
Half –life is depends on the systemic clearance and 
possibly be explained by the variability that was 
observed in the vancomycin systemic clearance and 
distribution volume of the SLED patients in Figure  5. 
In investigation the Vd of vancomycin ranged 0.43L/kg 
to 0.82L/kg  and systemic clearance ranged 10.88 
ml/min to 33.46 ml/min for the SLED patients . The 
mean of the systemic clearance is 16.91+6.99 and mean 
Vd  is 0.57+ 0.147. F6 and F5 membranes were mainly 
used in 10 patients with exceptionally one patient was 
employed with  the F7 membrane. 
Here its observed that the creatinine clearance of the 
patients SP-1 is 14.45 ml/min and SP-2 is 44.55 ml/min  
but according to that the systemic clearance of 
vancomycin is 10.88ml/min and 33.46ml/min 
respectively shown relatively less proportional to each 
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other and thus the inversely proportion to the half –life 
i.e, 40.76 hrs and 36.47 hrs too, while the volume of 
distribution is same. These may be due to the volume 
of distribution or protein drug binding mechanism.  
As finally after comparing the mean Half-life, volume 
of distribution & systemic clearance of the 
experimented values with the mean half-life of the 
reported Caucasian patients mention in Journal of 
Hospital Pharmacy, 2004[9]. We are getting reports of 
- Mean + SD half-life, volume of distribution, and 
systemic clearance, were 43.1 + 21.6 hours, 0.84 L/kg 
+ 0.17 L/kg, and 24.3 mL/min + 8.39 mL/min, 
respectively in Journal of Hospital Pharmacy, 2004. 
Thus the t-test of the means were 0.5828, degree of 
freedom (df) is 20; standard error of difference is 6.829 
and so, the two-tailed P value is 0.5665 i.e, P> 0.5 (this 
difference considered to be not significant). 
 
Conclusions 
In ethnic Indian SLED patients we found the T1/2  mean 
+ SD of 39.12 + 6.81 hrs compare to the Caucasian 
patients i.e, 43.1 + 21.6 hrs. And the t-test and P-value 
is 0.5828 & 0.5665 respectively. Thus it was concluded 
that the half-life of ethnic Indians patients having less 
in compare to Caucasians but this difference is not so 
significant. The half-lives of ethnic 8 patient is less 
then 40 out of 11 patients. 
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